US: BAYER, VALENTIS IN R&D DEAL
Article Abstract:
The blood clotting factor VIII is to be developed further by the two companies Bayer Corp of Pittsburgh and Valentis Inc. of Burlingame, California. The companies will use the Protomasc technology of Valentis to develop a coagulation factor with a longer circulation half-life in the body. In 1998 Bayer generated a turnover of more than US$ 400mn with the recombinant haemophilia treatment Kogenate. In August 1999 Valentis merged with the London-based company Polymasc Pharmaceuticals Plc.
Publication Name: Europa Chemie
Subject: Chemicals, plastics and rubber industries
ISSN: 0014-2484
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Deutsch-Italienischer Zusammenschlu in Elektrochemie
Article Abstract:
Effective from 01 Jul 1998, Italian group Oronzio De Nora (ODN), Milan took over the elecrochemistry business of German Heraeus Elektrochemie GmbH, Rodenbach and Heraeus De Nora Inc of Union, New Jersey. ODN is said to have the necessary potential to extend the electrochemistry business on an international basis. Heraeus Elektrochemie GmbH belonged to W.C. Heraeus GmbH (WCH), Hanau, a world leading company in the trade, separation and processing of precious metals.
Comment:
Takes over elecrochemistry business of German Heraeus Elektrochemie and Heraeus De Nora of Union, New Jersey
Publication Name: Europa Chemie
Subject: Chemicals, plastics and rubber industries
ISSN: 0014-2484
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: R hm gr ndet R hm America - keine Neuordnungbei Plexiglas Beiersdorf gr ndet japanisches Joint-venture Schweizer Tochter gegr ndet
- Abstracts: Henkel will in der Ukraine fertigen SPAIN: GERMAN HEMMELRATH TO BOOST SALES. JAPAN: PIGMENT PRODUCTION BY MERCK
- Abstracts: GERMANY: INITIATIVE FOR FLAT SCREENS. JAPAN: EISAI, KNOLL IN RESEARCH DEAL
- Abstracts: Krupp Uhde liefert D ngergranulierung nach Polen Krupp Uhde liefert B